J Korean Diabetes.  2022 Sep;23(3):165-177. 10.4093/jkd.2022.23.3.165.

Cognitive Dysfunction and Diabetes

• Jung CH
• Mok JO

• KMID: 2534302
• DOI: http://doi.org/10.4093/jkd.2022.23.3.165

Abstract

Diabetes mellitus and cognitive dysfunction are highly prevalent in the aging population. In the aging society, clinicians will be increasingly tasked with managing elderly patients who have both cognitive dysfunction and diabetes. A growing number of epidemiological and clinical studies confirmed that diabetes is associated with an increase in the risk of cognitive dysfunction and dementia. Cognitive dysfunction is of particular importance because it is associated with poor self-management ability, poor diabetes management with more frequent severe hypoglycemic episodes, and increased risk of cardiovascular morbidity and mortality. Current diabetes guidelines recommend screening for cognitive dysfunction in older and high-risk patients and providing individualized guidance for patients with cognitive dysfunction. Nonetheless, there is limited awareness among clinicians regarding this subject compared to other diabetic micro- and macrovascular complications. Recently, there has been increasing understanding in this field through multimodal neuroimaging and biomarkers for early detection of cognitive dysfunction in diabetes. In addition, new agents such as glucagon-like peptide 1 receptor agonists showed promising protective effects against cognitive dysfunction and dementia in patients with type 2 diabetes. In this review, we summarize the relationship between diabetes and cognitive dysfunction, especially dementia, and some contributing factors and pathogenesis of dementia in diabetes. We also review how anti-diabetic medications may influence cognitive dysfunction and clinical management guidance.

Keyword

Cognitive dysfunction; Dementia; Diabetes mellitus

Reference

1.Saedi E., Gheini MR., Faiz F., Arami MA. Diabetes mellitus and cognitive impairments. World J Diabetes. 2016. 7:412–22.

2.Alzheimer's Disease International. World Alzheimer report 2021. Available from: https://www.alzint.org/re-source/world-alzheimer-report-2021/.

3.Korean dementia observatory 2021. Available from: https://www.nid.or.kr/info/today_list.aspx.

4.American Psychiatric Association. Diagnostic and statis-tical manual of mental disorders (DSM-5). 5th ed.Washington, DC: American Psychiatric Publishing;2013.

5.Biessels GJ., Staekenborg S., Brunner E., Brayne C., Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 2006. 5:64–74. Erratum in: Lancet Neurol 2006;5):113.

6.Cheng G., Huang C., Deng H., Wang H. Diabetes as a risk factor for dementia and mild cognitive impairment: a me-ta-analysis of longitudinal studies. Intern Med J. 2012. 42:484–91.

7.Ha KH., Kim DJ. Current status of managing diabetes mellitus in Korea. Korean J Intern Med. 2016. 31:845–50.

8.Geldmacher DS., Whitehouse PJ. Evaluation of dementia. N Engl J Med. 1996. 335:330–6.

9.Kimm H., Lee PH., Shin YJ., Park KS., Jo J., Lee Y, et al. Mid-life and late-life vascular risk factors and dementia in Korean men and women. Arch Gerontol Geriatr. 2011. 52:e117–22.

10.Lyu F., Wu D., Wei C., Wu A. Vascular cognitive impairment and dementia in type 2 diabetes mellitus: an overview. Life Sci. 2020. 254:117771.

11.Ott A., Stolk RP., van Harskamp F., Pols HA., Hofman A., Breteler MM. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology. 1999. 53:1937–42.

12.Chatterjee S., Peters SA., Woodward M., Mejia Arango S., Batty GD., Beckett N, et al. Type 2 diabetes as a risk factor for dementia in women compared with men: a pooled analysis of 2.3 million people comprising more than 100,000 cases of dementia. Diabetes Care. 2016. 39:300–7.

13.Celis-Morales CA., Franzén S., Eeg-Olofsson K., Nauclér E., Svensson AM., Gudbjornsdottir S, et al. Type 2 diabetes, glycemic control, and their association with dementia and its major subtypes: findings from the Swedish National Diabetes Register. Diabetes Care. 2022. 45:634–41.

14.Haroon NN., Austin PC., Shah BR., Wu J., Gill SS., Booth GL. Risk of dementia in seniors with newly diagnosed diabetes: a population-based study. Diabetes Care. 2015. 38:1868–75.

15.Biessels GJ., Strachan MW., Visseren FL., Kappelle LJ., Whitmer RA. Dementia and cognitive decline in type 2 diabetes and prediabetic stages: towards targeted inter-ventions. Lancet Diabetes Endocrinol. 2014. 2:246–55.

16.Smolina K., Wotton CJ., Goldacre MJ. Risk of dementia in patients hospitalised with type 1 and type 2 diabetes in England, 1998-2011: a retrospective national record link-age cohort study. Diabetologia. 2015. 58:942–50.

17.Whitmer RA., Biessels GJ., Quesenberry CP Jr., Liu JY., Karter AJ., Beeri M. Type 1 diabetes and risk of dementia in late life: the Kaiser diabetes and cognitive aging study. Alzheimers Dement. 2015. 11(7S Pt 3):132–3.

18.Jacobson AM., Ryan CM., Cleary PA., Waberski BH., Weinger K., Musen G, et al. Biomedical risk factors for decreased cognitive functioning in type 1 diabetes: an 18 year follow-up of the Diabetes Control and Complications Trial (DCCT) cohort. Diabetologia. 2011. 54:245–55.

19.Jacobson AM., Ryan CM., Braffett BH., Gubitosi-Klug RA., Lorenzi GM., Luchsinger JA, et al. Cognitive performance declines in older adults with type 1 diabetes: results from 32 years of follow-up in the DCCT and EDIC Study. Lancet Diabetes Endocrinol. 2021. 9:436–45.

20.Launer LJ., Miller ME., Williamson JD., Lazar RM., Gerstein HC., Murray AM., ACCORD MIND investigators, et al. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol. 2011. 10:969–77.

21.Tuligenga RH. Intensive glycaemic control and cognitive decline in patients with type 2 diabetes: a meta-analysis. Endocr Connect. 2015. 4:R16–24.

22.Leys D., Hénon H., Mackowiak-Cordoliani MA., Pasquier F. Poststroke dementia. Lancet Neurol. 2005. 4:752–9.

23.Derakhshan F., Toth C. Insulin and the brain. Curr Diabetes Rev. 2013. 9:102–16.

24.Arnold SE., Arvanitakis Z., Macauley-Rambach SL., Koenig AM., Wang HY., Ahima RS, et al. Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nat Rev Neurol. 2018. 14:168–81.

25.Burillo J., Marqués P., Jiménez B., González-Blanco C., Beni-to M., Guillén C. Insulin resistance and diabetes mellitus in Alzheimer's disease. Cells. 2021. 10:1236.

26.Tumminia A., Vinciguerra F., Parisi M., Frittitta L. Type 2 diabetes mellitus and Alzheimer's disease: role of insulin signalling and therapeutic implications. Int J Mol Sci. 2018. 19:3306.

27.de la Monte SM., Wands JR. Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol. 2008. 2:1101–13.

28.Rivera EJ., Goldin A., Fulmer N., Tavares R., Wands JR., de la Monte SM. Insulin and insulin-like growth factor ex-pression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimers Dis. 2005. 8:247–68.

29.Moreira PI. Alzheimer's disease and diabetes: an integrative view of the role of mitochondria, oxidative stress, and insulin. J Alzheimers Dis. 2012. 30(Suppl 2):S199–215.

30.Spauwen PJ., van Eupen MG., Köhler S., Stehouwer CD., Verhey FR., van der Kallen CJ, et al. Associations of ad-vanced glycation end-products with cognitive functions in individuals with and without type 2 diabetes: the Maas-tricht study. J Clin Endocrinol Metab. 2015. 100:951–60.

31.Ly H., Despa F. Diabetes-related amylin dyshomeostasis: a contributing factor to cerebrovascular pathology and dementia. J Lipid Atheroscler. 2019. 8:144–51.

32.Cline EN., Bicca MA., Viola KL., Klein WL. The amyloid-β oligomer hypothesis: beginning of the third decade. J Alzheimers Dis. 2018. 64(S1):S567–610.

33.Ferreira ST., Clarke JR., Bomfim TR., De Felice FG. Inflam-mation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease. Alzheimers Dement. 2014. 10(1 Suppl):S76–83.

34.van Sloten TT., Sedaghat S., Carnethon MR., Launer LJ., Stehouwer CDA. Cerebral microvascular complications of type 2 diabetes: stroke, cognitive dysfunction, and depression. Lancet Diabetes Endocrinol. 2020. 8:325–36.

35.Tamaki C., Ohtsuki S., Terasaki T. Insulin facilitates the he-patic clearance of plasma amyloid beta-peptide (1 40) by intracellular translocation of low-density lipoprotein re-ceptor-related protein 1 (LRP-1) to the plasma membrane in hepatocytes. Mol Pharmacol. 2007. 72:850–5.

36.Sheen YJ., Sheu WH. Association between hypoglycemia and dementia in patients with type 2 diabetes. Diabetes Res Clin Pract. 2016. 116:279–87.

37.Exalto LG., Biessels GJ., Karter AJ., Huang ES., Katon WJ., Minkoff JR, et al. Risk score for prediction of 10 year dementia risk in individuals with type 2 diabetes: a cohort study. Lancet Diabetes Endocrinol. 2013. 1:183–90.

38.Biessels GJ., Whitmer RA. Cognitive dysfunction in diabetes: how to implement emerging guidelines. Diabetologia. 2020. 63:3–9.

39.Chin SO., Rhee SY., Chon S., Baik SH., Park Y., Nam MS, et al. Hypoglycemia is associated with dementia in elderly patients with type 2 diabetes mellitus: an analysis based on the Korea National Diabetes Program Cohort. Diabetes Res Clin Pract. 2016. 122:54–61.

40.Koekkoek PS., Kappelle LJ., van den Berg E., Rutten GE., Biessels GJ. Cognitive function in patients with diabetes mellitus: guidance for daily care. Lancet Neurol. 2015. 14:329–40.

41.Yang Y., Zhao JJ., Yu XF. Expert consensus on cognitive dysfunction in diabetes. Curr Med Sci. 2022. 42:286–303.

42.Moran C., Than S., Callisaya M., Beare R., Srikanth V. New horizons-cognitive dysfunction associated with type 2 diabetes. J Clin Endocrinol Metab. 2022. 107:929–42.

43.Biessels GJ., Despa F. Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications. Nat Rev Endocrinol. 2018. 14:591–604.

44.Biessels GJ., Nobili F., Teunissen CE., Simó R., Scheltens P. Understanding multifactorial brain changes in type 2 diabetes: a biomarker perspective. Lancet Neurol. 2020. 19:699–710.

45.Korean Diabetes Association. Clinical practice guidelines for diabetes. Available from: http://kdaguideline.com/ (updated 2021 Dec 1).

46.American Diabetes Association Professional Practice Committee., Draznin B., Aroda VR., Bakris G., Benson G., Brown FM, et al. 13. Older adults: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022. 45(Suppl 1):S195–207.

47.LeRoith D., Biessels GJ., Braithwaite SS., Casanueva FF., Draznin B., Halter JB, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2019. 104:1520–74.

48.Muñoz-Jiménez M., Zaarkti A., García-Arnés JA., García-Casares N. Antidiabetic drugs in Alzheimer's disease and mild cognitive impairment: a systematic review. Dement Geriatr Cogn Disord. 2020. 49:423–34.

49.Chen Q., Cao T., Li N., Zeng C., Zhang S., Wu X, et al. Re-purposing of anti-diabetic agents as a new opportunity to alleviate cognitive impairment in neurodegenerative and neuropsychiatric disorders. Front Pharmacol. 2021. 12:667874.

50.Michailidis M., Tata DA., Moraitou D., Kavvadas D., Ka-rachrysafi S., Papamitsou T, et al. Antidiabetic drugs in the treatment of Alzheimer's disease. Int J Mol Sci. 2022. 23:4641.

51.Benedict C., Frey WH 2nd., Schiöth HB., Schultes B., Born J., Hallschmid M. Intranasal insulin as a therapeutic option in the treatment of cognitive impairments. Exp Gerontol. 2011. 46:112–5.

52.Risner ME., Saunders AM., Altman JF., Ormandy GC., Craft S., Foley IM., Rosiglitazone in Alzheimer's Disease Study Group, et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J. 2006. 6:246–54.

53.Grieco M., Giorgi A., Gentile MC., d'Erme M., Morano S., Maras B, et al. Glucagon-like peptide-1: a focus on neurodegenerative diseases. Front Neurosci. 2019. 13:1112.

54.Li Y., Li L., Hölscher C. Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases. Rev Neurosci. 2016. 27:689–711.

55.Hölscher C. Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkin-son's disease models. Neuropharmacology. 2018. 136(Pt B):251–9.

56.Sim AY., Barua S., Kim JY., Lee YH., Lee JE. Role of DPP-4 and SGLT2 inhibitors connected to Alzheimer disease in type 2 diabetes mellitus. Front Neurosci. 2021. 15:708547.

57.Kim YG., Jeon JY., Kim HJ., Kim DJ., Lee KW., Moon SY, et al. Risk of dementia in older patients with type 2 diabetes on dipeptidyl-peptidase IV inhibitors versus sulfony-lureas: a real-world population-based cohort study. J Clin Med. 2018. 8:28. Erratum in: J Clin Med 2019;8):389.

58.Weinstein G., Davis-Plourde KL., Conner S., Himali JJ., Beiser AS., Lee A, et al. Association of metformin, sulfo-nylurea and insulin use with brain structure and function and risk of dementia and Alzheimer's disease: pooled analysis from 5 cohorts. PLoS One. 2019. 14:e0212293.

59.Rizzo MR., Di Meo I., Polito R., Auriemma MC., Gambar-della A., di Mauro G, et al. Cognitive impairment and type 2 diabetes mellitus: focus of SGLT2 inhibitors treatment. Pharmacol Res. 2022. 176:106062.